Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Although kinase inhibitors raise hope for people with cancer, patients and their clinicians are commonly confronted with the cutaneous side-effects that are associated with the use of these drugs. This review is the result of collaborations between dermatologists, medical oncologists, and pathologists, and discusses the cutaneous side-effects seen after treatment with the inhibitors of epidermal-growth-factor receptor (EGFR), imatinib, sorafenib, and sunitinib. Some of the side-effects caused by these agents are very distressing, partly because they are chronic owing to the long duration of treatment. Therefore, patients need early and appropriate dermatological management. Moreover, several studies have reported a link between the antitumour efficacy of EGFR inhibitors and cutaneous side-effects. Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response.
Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France. crobert@igr.fr
Caroline
C
Robert
Jean-Charles
JC
Soria
Alain
A
Spatz
Axel
A
Le Cesne
David
D
Malka
Patricia
P
Pautier
Janine
J
Wechsler
Catherine
C
Lhomme
Bernard
B
Escudier
Valérie
V
Boige
Jean-Pierre
JP
Armand
Thierry
T
Le Chevalier
D019138:Antibodies, Blocking; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001557:Benzenesulfonates / Q000009:adverse effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006201:Hair Diseases / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D009260:Nail Diseases / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000009:adverse effects; D011743:Pyrimidines / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced*; D000077157:Sorafenib
D019138:Antibodies, Blocking; D000970:Antineoplastic Agents; D001549:Benzamides; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases